THOMAS WHEELER to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications THOMAS WHEELER has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.041
-
The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem Suppl. 1994; 19:283-9.
Score: 0.026
-
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
Score: 0.015